Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type

Type

Guidance programme

Advice programme

Showing 1001 to 1010 of 2418

TitleReference numberPublishedLast updated
Ibrutinib for treating relapsed or refractory mantle cell lymphomaTA502
Ibrutinib for treating Waldenstrom's macroglobulinaemiaTA795
Ibrutinib for untreated chronic lymphocytic leukaemia without a 17p deletion or TP53 mutation (terminated appraisal)TA452
Ibrutinib with bendamustine and rituximab for treating relapsed or refractory chronic lymphocytic leukaemia after systemic therapy (terminated appraisal)TA437
Ibrutinib with obinutuzumab for untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (terminated appraisal)TA702
Ibrutinib with rituximab for treating Waldenstrom's macroglobulinaemia (terminated appraisal)TA608
Ibrutinib with rituximab for untreated chronic lymphocytic leukaemia (terminated appraisal)TA703
Ibrutinib with venetoclax for untreated chronic lymphocytic leukaemiaTA891
Icare rebound tonometer to measure intraocular pressureMIB57
icobrain ms for active relapsing–remitting multiple sclerosisMIB291

Results per page

  1. 10
  2. 25
  3. 50
  4. All